Botulinum Toxin Type A
drugOn this page
Also known as Agn-151607Ant-1401Ant-1403BotuliftBotulinum a toxinBtx-aCunoxNeuronoxNuceivaRTI-150RTI150
Summary
Botulinum Toxin Type A (CHEMBL4297862) is an approved protein; indicated across 11 conditions including overactive bladder and migraine disorder.
At a glance
- Status: Approved (max clinical phase 4)
- Modality: Protein
- Indications: 11 conditions
- Clinical trials: 300
Identifiers
Drug identity and classification
| Field | Value |
|---|---|
| ChEMBL ID | CHEMBL4297862 |
| Name | Botulinum Toxin Type A |
| Type | Protein |
| Max phase | 4 |
Also known as: Agn-151607, Ant-1401, Ant-1403, Botulift, Botulinum a toxin, Botulinum toxin type a, Btx-a, Cunox, Neuronox, Nuceiva, RTI-150, RTI150
Targets
Targets
No target linkage available.
Bioactivity
No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).
Target pathways
No target-pathway data for this drug (no mapped target genes).
Indications & clinical
Indications
11 indications (4 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).
| Indication | Trial phase | MONDO | EFO |
|---|---|---|---|
| overactive bladder | 4 | MONDO:0006624 | EFO:1000781 |
| migraine disorder | 4 | MONDO:0005277 | MONDO:0005277 |
| benign essential blepharospasm | 3 | MONDO:0011728 | Orphanet:93955 |
| arthropathy | 2 | MONDO:0006816 | EFO:1000999 |
7 further indication records had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.
Clinical trials
Total trials: 300.
Phase distribution
| Phase | Trials |
|---|---|
| PHASE3 | 84 |
| Not specified | 68 |
| PHASE2 | 64 |
| PHASE4 | 47 |
| PHASE1/PHASE2 | 13 |
| PHASE2/PHASE3 | 8 |
| PHASE1 | 8 |
| EARLY_PHASE1 | 8 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT03654066 | PHASE4 | ENROLLING_BY_INVITATION | Botox or Botox With Esophageal Dilation in Patients With Achalasia |
| NCT05112081 | PHASE4 | NOT_YET_RECRUITING | Evaluation of Botox Treatment on Chronical Scrotal Pain |
| NCT06356025 | PHASE4 | ACTIVE_NOT_RECRUITING | Botulinum Toxin Injection in the UES for R-CPD |
| NCT06448676 | PHASE4 | NOT_YET_RECRUITING | Head-to-Head Comparison of All Botulinum Neurotoxin Type A Products for Glabellar Rhytides |
| NCT00168415 | PHASE4 | COMPLETED | A Study Using Botulinum Toxin Type A in Adolescents With Axillary Hyperhidrosis |
| NCT00168480 | PHASE4 | COMPLETED | A Study Using Botulinum Toxin Type A in Patients With Axillary Hyperhidrosis |
| NCT00175123 | PHASE4 | UNKNOWN | Effect of Botulinum Toxin in Neurogenic Bladders in Children With Myelomeningocele |
| NCT00179114 | PHASE4 | COMPLETED | Vanderbilt University Spasticity Management Program Evaluation Plan |
| NCT00216411 | PHASE4 | COMPLETED | Effects on Quality of Life Following Dysport Treatment in Post-stroke Spasticity of the Arm |
| NCT00234546 | PHASE4 | COMPLETED | Asian Botulinum Clinical Trial Designed for Early Stroke Spasticity |
| NCT00432341 | PHASE4 | TERMINATED | Efficacy and Safety of Two Different Botulinum Toxin Type A Treatments for Moderate to Severe Cervical Dystonia |
| NCT00434863 | PHASE4 | COMPLETED | Comparative Study of the Effect of Dysport and Botox |
| NCT00477802 | PHASE4 | TERMINATED | Botulinum Toxin Type A (Botox) in the Management of Levodopa-Induced Peak-Dose Dyskinesias in Parkinson’s Disease |
| NCT00528541 | PHASE4 | COMPLETED | Comparison of Efficacy and Safety of Two Different Types of Botulinum Toxin Type A in Moderate to Severe Cervical Dystonia |
| NCT00549783 | PHASE4 | COMPLETED | BOTOX® Economic Spasticity Trial (BEST) |
| NCT00761592 | PHASE4 | COMPLETED | Comparison of Two Botulinum Type A Products in the Treatment of Blepharospasm |
| NCT00856414 | PHASE4 | COMPLETED | Patient Satisfaction With Treatment of BOTOX® Cosmetic for the Temporary Correction of Moderate to Severe Glabellar Lines |
| NCT00908050 | PHASE4 | COMPLETED | Study of the Safety and Efficacy of Botox in Bruxism |
| NCT00989768 | PHASE4 | COMPLETED | Field of Effects of Two Commercial Preparations of Botulinum Toxin Type A |
| NCT01004042 | PHASE4 | COMPLETED | Quality of Life and Self-esteem After Botox® Injections in Depressed and Non-depressed Patients |
| NCT01045694 | PHASE4 | TERMINATED | Botulism Toxin Injection as a Treatment for Arthritis of the Basal Thumb Joint |
| NCT01251211 | PHASE4 | COMPLETED | Botulinum Toxin in Peripheral Neuropathic Pain |
| NCT01256021 | PHASE4 | COMPLETED | The Efficacy and Safety of MEDITOXIN® in Children With Cerebral Palsy |
| NCT01259557 | PHASE4 | COMPLETED | Efficacy and Safety Study of Meditoxin® to Treat Essential Blepharospasm |
| NCT01271452 | PHASE4 | COMPLETED | Safety and Efficacy of Two Types of Botulinum Toxin Type A For the Treatment of Glabellar Lines |
| NCT01272414 | PHASE4 | WITHDRAWN | Use of Botox in the Management of Thyroid Related Upper Eyelid Retraction |
| NCT01276015 | PHASE4 | COMPLETED | Spread And Effectiveness Of Botulinum Neurotoxin A In Spastic Equinus In Cerebral Palsy |
| NCT01384214 | PHASE4 | COMPLETED | Effect of Botulinum Toxin Type A on Swallowing in Patients With Cervical Dystonia |
| NCT01391312 | PHASE4 | COMPLETED | Patient Satisfaction Study of BOTOX® Cosmetic in the Treatment of Moderate to Severe Frown Lines |
| NCT01460355 | PHASE4 | COMPLETED | Comparison of Two Treatments for Strabismus Correction: Botulinum Toxin A Associated to Surgery and Surgery Alone |
| NCT01579500 | PHASE4 | COMPLETED | Neuropathic Pain Study With Botulinum Toxin A in Spinal Cord Injury Patients |
| NCT01814670 | PHASE4 | COMPLETED | Treatment With Botulinum Toxin Type A (BOTOX®) in Chinese Patients With Moderate to Severe Frown Lines |
| NCT02147561 | PHASE4 | COMPLETED | A Safety and Efficacy Study of BOTOX® in Korean Adults With Chronic Migraine |
| NCT02321436 | PHASE4 | COMPLETED | Study to Assess Impact of Dysport Injections Early After Stroke on Upper Limb Spasticity Progression |
| NCT02462317 | PHASE4 | COMPLETED | Study of the Effects on Motor Recovery of Early Post-stroke Spasticity Treatment |
| NCT02601287 | PHASE4 | COMPLETED | A Safety and Efficacy Study of Botulinum Toxin Type A (BOTOX®) to Treat Urinary Incontinence Due to Neurogenic Detrusor Overactivity or Overactive Bladder in Korean Patients |
| NCT02829281 | PHASE4 | UNKNOWN | Intra-articular Botox Type A Versus Corticosteroids in Knee Osteoarthritis |
| NCT02969356 | PHASE4 | COMPLETED | Study to Evaluate Effects of DYSPORT® Injected in Lower and Upper Limb Combined With Guided Self-Rehabilitation Contract (GSC) |
| NCT03381261 | PHASE4 | COMPLETED | (Botox) Mechanisms of Action in Altering the Molecular Environment in Which Pain Fibers Exist |
| NCT03508882 | PHASE4 | COMPLETED | Pretarsal Versus Preseptal Botulinum Toxin for Patients With Eyelid Spasm |
Clinical evidence (CIViC)
No CIViC predictive evidence (expected for non-precision-medicine drugs).
Pharmacology
Pharmacogenomics
No PharmGKB pharmacogenomic data curated for this drug.
Related molecules
Related molecules
No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).